Bluebird Bio | BLUE

Bluebird Bio traded at $4.51 this Monday March 27th, increasing $0.08 or 1.81 percent since the previous trading session. Looking back, over the last four weeks, Bluebird Bio gained 13.27 percent. Over the last 12 months, its price fell by 8.70 percent. Looking ahead, we forecast Bluebird Bio to be priced at 4.29 by the end of this quarter and at 3.89 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Agios Pharmaceuticals 22.25 0.51 2.35% -21.98%
Alnylam Pharmaceuticals 190.51 0.53 0.28% 17.85%
Amgen 237.49 0.73 0.31% -1.68%
Arrowhead Research 24.43 0.14 0.58% -45.44%
Avrobio Inc 1.10 0.13 12.82% -23.61%
Biogen 270.61 0.63 0.23% 27.84%
Bluebird Bio 4.51 0.08 1.81% -8.70%
BioMarin Pharmaceutical 91.50 0.76 0.84% 16.77%
Gilead Sciences 80.16 0.58 0.73% 32.43%
Intercept Pharmaceuticals 13.83 0.37 2.75% -16.28%
Immunogen 3.81 0.02 0.53% -12.41%
Incyte Corp 70.95 0.14 0.20% -10.13%
Ionis Pharmaceuticals 33.72 -0.23 -0.68% -6.02%
Moderna Inc 147.66 -0.69 -0.47% -14.69%
Mirati Therapeutics 37.58 -1.52 -3.89% -52.88%
Nektar Therapeutics 0.77 0.05 7.31% -86.12%
Novartis 82.24 -0.01 -0.01% 0.83%
Pfizer 40.21 -0.01 -0.02% -24.53%
PTC Therapeutics 45.76 1.59 3.60% 26.34%
Ultragenyx Pharmaceutical 37.33 -0.35 -0.93% -45.08%
Regeneron Pharmaceuticals 824.00 3.59 0.44% 17.98%
Seattle Genetics 199.60 1.96 0.99% 42.88%
Sangamo BioSciences 1.74 0.08 4.82% -69.63%
Sarepta Therapeutics 131.14 0.95 0.73% 72.39%
Vertex Pharmaceuticals 310.41 1.94 0.63% 20.32%

Indexes Price Day Year
USND 11769 -55.12 -0.47% -18.02%
US2000 1754 18.75 1.08% -15.61%

Bluebird Bio
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.